Vertex’s Sickle Cell Treatment Gets December Decision Date, On Track To Be First CRISPR Therapy
Rival Therapy Could Also Get Green Light By Year End
Vertex now looks likely to gain US approval for the first ever CRISPR gene edited therapy by the end of the year, but could face immediate competition from Bluebird Bio.
